Um die volle Funktionalität der Webseite nutzen zu können, müssen Sie JavaScript in ihrem Browser aktivieren.

DAX19.390,04+0,87 %

Gold2.656,990,00 %

Öl (Brent)79,04-0,57 %

Dow Jones42.865,63+0,97 %

US Tech 10020.269,38+0,14 %

EUR/USD1,09379+0,02 %

Top 15 der gesamten Suchanfragen der letzten 7 Tage

Login

Ultimovacs Aktie

Aktie

ISIN: NO0010851603 WKN: A2PKSD Land Flagge NO

Norwegen

Zur Watchlist hinzufügen Zum Portfolio hinzufügen

Zum Portfolio hinzufügen

0,1533

EUR

+6,24 %

+0,0090 EUR

Letzter Kurs 11.10.24 Lang & Schwarz

Geldkurs

11.10.24

0,1386

EUR

38.580 STK

Briefkurs

11.10.24

0,1680

EUR

38.580 STK

Ultimovacs Aktie kaufen

Neueste Nachrichten

Ultimovacs Announces Patient Recruitment Discontinuation in LUNGVAC Trial Investigating UV1 Combined with Checkpoint Inhibitor Therapy in Non-Small Cell Lung Cancer 11.09.24 · globenewswire · Ultimovacs
Ultimovacs Announces Updated Data Analysis on UV1 Phase II NIPU Trial in Mesothelioma at ESMO 2024 09.09.24 · globenewswire · Ultimovacs
Ultimovacs ASA Reports Second Quarter 2024 Financial Results and Provides General Business Update 21.08.24 · globenewswire · Ultimovacs
Ultimovacs ASA: Invitation to second quarter 2024 results webcast presentation 15.08.24 · globenewswire · Ultimovacs
Ultimovacs Announces Notice of Resignation from Deputy Board Member 07.08.24 · globenewswire · Ultimovacs
Ultimovacs Announces Topline Data from FOCUS Phase II Trial of UV1 Combined with Pembrolizumab in Patients with Metastatic or Recurrent Head and Neck Cancer 05.08.24 · globenewswire · Ultimovacs
Ultimovacs Announces Poster Presentation of NIPU Phase II Trial Update at Upcoming ESMO Congress 2024 01.08.24 · globenewswire · Ultimovacs
Ultimovacs ASA announces revised terms of the employee share option program 24.06.24 · globenewswire · Ultimovacs
Ultimovacs provides update from Phase I study in malignant melanoma: Continued strong overall survival in patients treated with UV1 cancer vaccine and pembrolizumab 11.06.24 · globenewswire · Ultimovacs
Ultimovacs Announces Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting 01.06.24 · globenewswire · Ultimovacs
Ultimovacs ASA Reports First Quarter 2024 Financial Results and Provides General Business Update 07.05.24 · globenewswire · Ultimovacs
Ultimovacs ASA: Invitation to first quarter 2024 results webcast presentation 30.04.24 · globenewswire · Ultimovacs

1
2
3
…
4

Meistgelesen

12 Monate

Ultimovacs Announces Patient Recruitment Discontinuation in LUNGVAC Trial Investigating UV1 ... 612 Leser
Ultimovacs ASA Reports Second Quarter 2024 Financial Results and Provides General Business Update 524 Leser
Ultimovacs ASA: Invitation to second quarter 2024 results webcast presentation 456 Leser
Ultimovacs Announces Updated Data Analysis on UV1 Phase II NIPU Trial in Mesothelioma at ESMO 2024 292 Leser
Ultimovacs ASA Reports First Quarter 2024 Financial Results and Provides General Business Update 260 Leser
Ultimovacs ASA: Mandatory notification of trade by primary insiders 240 Leser
Ultimovacs Announces Topline Results from INITIUM Study Evaluating UV1 Vaccination Added to ... 240 Leser
Ultimovacs Announces Notice of Resignation from Deputy Board Member 232 Leser
Ultimovacs ASA: Annual Report 2023 224 Leser
Ultimovacs ASA: Mandatory notification of trade by primary insider 216 Leser